Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ProQR Therapeutics (PRQR) FCF Margin (2021 - 2022)

ProQR Therapeutics' FCF Margin history spans 2 years, with the latest figure at 2154.72% for Q4 2022.

  • On a quarterly basis, FCF Margin fell 383255.0% to 2154.72% in Q4 2022 year-over-year; TTM through Sep 2023 was 373.2%, a 108579.0% increase, with the full-year FY2025 number at 338.31%, down 13830.0% from a year prior.
  • FCF Margin hit 2154.72% in Q4 2022 for ProQR Therapeutics, down from 1857.25% in the prior quarter.
  • Over the last five years, FCF Margin for PRQR hit a ceiling of 1677.82% in Q4 2021 and a floor of 4085.19% in Q2 2021.